Germany In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Germany In-Vitro Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Germany In-Vitro Diagnostics market is expected to register a CAGR of 5.6% over the forecast period, 2022-2027.

In Germany, due to the COVID-19 pandemic, the demand for in-vitro diagnostic products has increased due to the sharp rise in demand for polymerase chain reaction (PCR), next-generation sequencing (NGS), serology-based rapid-test products, the supportive regulatory landscape for product development and commercialization, and a rapid rise in target patient population which has boosted the market growth. Moreover, these factors have allowed the market players to improve and strengthen their current manufacturing and distribution capabilities as well as to focus on product commercialization and upgrades.

For instance, In March 2021, an ultrasensitive molecular test was developed by the University of California. This test is based on a chip technology that could detect the presence of influenza A and SARS-CoV-2 antigens. The test is under further study for conversion into a Point-of-Care (POC) test. There has been a shift in the industry dynamics, with the rising number of players focusing on launching tests for home-based testing. Moreover, in 2021, the Food and drug administration prioritized home-based molecular diagnostic tests. For instance, In March 2021, BATM Advanced Communications Ltd. announced the launch of its molecular diagnostics self-test kit for the detection of COVID-19. Thus, the rising tests and novel product launches are boosting the market's growth during a pandemic.

Also, in February 2020, Altona Diagnostics GmbH (Germany) launched the RealStar SARS-CoV-2 RT-PCR Kit 1.0 for detecting coronavirus using PCR. Thus, this increase in newer diagnostic kits will boost the adoption of in-vitro diagnostics, thereby providing lucrative opportunities for the growth of the in-vitro diagnostics market in the upcoming years.

In addition, in June 2020, CENTOGENE partnered exclusively with Lufthansa and with Fraport to offer First Walk-In COVID-19 Testing Facility to passengers flying to and from Frankfurt Airport (FRA) in Germany.

The factors such as the rising number of cases of chronic diseases, increasing aging population, increasing demand for accurate diagnosis, and favorable government initiatives are the key driving factor for the growth of the in-vitro diagnostics market in Germany. For instance, according to the GLOBOCAN report of 2020, about 628,519 new cases of cancer were diagnosed 2020 in Germany. Breast and colorectum cancer were more prevalent in females while in males prostate and lung cancer were more prevalent in the country.

In addition, as per the 2021 report of the International Diabetes Federation (IDF), there were about 6.2 million people in Germany with diabetes. This number is projected to reach 6.5 million by 2030 which is further expected to boost the studied market’s growth over the forecast period.

Innovative developments in the in vitro diagnostics field are currently driven by four major trends: point-of-care testing, automation, digitalization, and the concept of personalized medicine. Also, factors contributing to the growth of the market include a rapid increase in the infectious disease population, technological advances, a rapidly aging population, and the advent of point-of-care diagnostics. For instance, as per the report published in 2020, human immunodeficiency viruses (HIV) outcomes: Beyond Viral Suppression, there were around 86,000 people in Germany living with human immunodeficiency viruses (HIV) whereas around 20% of the diseased population were living in Berlin. The high burden of these infectious diseases is expected to boost the demand for in-vitro diagnostics tests in this country.

The market players are adopting various strategies such as product launches, developments, collaborations, and expansions to increase market share. For instance, In October 2020, Siemens Healthineers AG (Germany) launched the CLINITEST Rapid COVID-19 Antigen Test to identify individuals infected with the coronavirus in 15 minutes to avoid the spread of COVID-19. However, factors limiting the growth of the market are a lack of proper reimbursement policies and a cumbersome regulatory framework.

Key Market TrendsThe Molecular Diagnostic Segment is Expected to Witness Growth Over the Forecast Period

Molecular diagnostics are used to analyze biological markers in the genome and proteome to detect pathogens or mutations. The article “Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients, published by Christian Ihling, Charles Tanford Center, Halle, Germany, published in 2020, stated that mass spectrometry delivered valuable diagnostic data that complement genomic information and allow to increase the current knowledge of the COVID-19 disease caused by the SARS-CoV-2 virus. Such studies in the region using mass spectrometers increase the awareness and demand for these devices.

Nucleic acid amplification technology for molecular diagnostics is the gold standard method for the detection of viruses and has been increasingly adopted. The market players are constantly focusing on product launches based on nucleic acid amplification and product development strategies for COVID-19. For instance, in May 2021, XPhyto Therapeutics Corp. has announce that its distribution, storage, and logistics partner, Max Pharma GmbH, launched the sale of its 25-minute SARS-CoV-2 (COVID-19) RT-PCR test system (“Covid-ID Lab”) in Germany.

In May 2021, in Germany, Seegene Germany GmbH is taking part in the government's Back-to-School program called the "Lolli-Test," a starting point in returning our daily lives to normalcy. Under the program, Seegene Germany GmbH will be supplying COVID-19 diagnostic tests to laboratories, in business with the federal government, worth up to 19.3 million Euros.

Based on the technology used, molecular diagnostic devices can be segmented into chips and microarrays, mass spectroscopy, next-generation sequencing (NGS), polymerase chain reaction (PCR)-based methods, cytogenetics, and molecular imaging. Molecular diagnostics has emerged as one of the largest and fastest growing sectors of the in-vitro diagnostics industry in Germany. This development is fueled by the introduction of powerful techniques, such as real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS), which allow the amplification and decoding of genetic and epigenetic information.

Initiatives in strategies such as new product development, collaborations, acquisitions, and funding in research and development are adopted by key players to secure their positions in the German market. For instance, in March 2021, German company ZytoVision GmbH entered into a distribution agreement with Bio SB for the distribution of line ZytoVision of CE-approved chromogenic in situ hybridization and fluorescent in situ hybridization probes targeted for use in lung carcinomas. Hence, owing to the above-mentioned factors it is expected to drive the segment growth over the forecast period.

Competitive Landscape

The Germany In-Vitro Diagnostics market is fragmented and competitive. The market has rapidly evolved over the last few years. Industry observed significant changes in adopting market strategies such as product developments, mergers, and acquisitions in recent years. Thus, the German In-Vitro Diagnostics market has become a very competitive industry. Major companies in the market are Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories Inc., bioMerieux SA, Danaher Corporation, Epigenomics Inc., F. Hoffmann-La Roche Ltd, Johnson & Johnson, Qiagen N.V., and Siemens Healthcare GmbH.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.